The metabolites obtained from Lophophora williamsii, like those of many
other cacti, constitute a potential still little exploited in the
pharmaceutical industry (Das et al., 2020), and have not aroused
business desires similar to those of ayahuasca, possibly due to
the results of the legal conflict surrounding the latter.